DOCSLIB.ORG

Blanchfield-Army.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Blanchfield-Army.Pdf BLANCHFIELD ARMY COMMUNITY HOSPITAL OUTPATIENT FORMULARY Alphabetical Listing by Name This document is current as of February 24, 2021. The availability of formulary items is subject to change. 1 ABACAVIR, DOLUTEGRAVIR, AND LAMIVUDINE Abacavir, Dolutegravir, and Lamivudine Acyclovir (Systemic) Outpatient Dosage Forms Outpatient Dosage Forms Tablet, Oral: Capsule, Oral: Triumeq: Abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg Generic: 200 mg [BCF] Suspension, Oral: Abemaciclib Generic: 200 mg/5 mL [BCF] Outpatient Dosage Forms Tablet, Oral: Tablet, Oral: Generic: 400 mg [BCF], 800 mg [BCF] Verzenio: 150 mg Acyclovir (Topical) Abiraterone Acetate Outpatient Dosage Forms Outpatient Dosage Forms Cream, External: Tablet, Oral: Generic: 5% (5 g) Generic: 500 mg Ointment, External: Generic: 5% (15 g) Acamprosate Outpatient Dosage Forms Adalimumab Tablet Delayed Release, Oral, as calcium: Outpatient Formulary Brands Available Humira Generic: 333 mg Outpatient Dosage Forms Kit, Subcutaneous [preservative free]: Acarbose Humira: 40 mg/0.8 mL [contains polysorbate 80] [BCF] Outpatient Dosage Forms Pen-injector Kit, Subcutaneous [preservative free]: Tablet, Oral: Humira Pen: 40 mg/0.4 mL (1 ea)[contains polysorbate 80] [BCF] Generic: 25 mg, 50 mg Humira Pen-CD/UC/HS Starter: 80 mg/0.8 mL (1 ea) [contains polysorbate 80] [BCF] Acetaminophen Humira Pen-Psor/Uveit Starter: 80 MG/0.8ML & 40MG/0.4ML (1 ea) [contains Outpatient Dosage Forms polysorbate 80] [BCF] Caplet, Oral: Prefilled Syringe Kit, Subcutaneous [preservative free]: Generic: 500 mg Humira: 20 mg/0.4 mL (1 ea) [BCF]; 20 mg/0.2 mL (1 ea) [BCF]; 40 mg/0.4 Suppository, Rectal: mL (1 ea) [BCF] [contains polysorbate 80] Generic: 120 mg (12s) Humira Pediatric Crohns Start: 80 mg/0.8 mL (1 ea) [BCF] [contains poly- Suspension, Oral: sorbate 80] Generic: 160 mg/5 mL (120 mL) Tablet, Oral: Adapalene Generic: 325 mg (bottle of 100 tablets) Outpatient Dosage Forms Cream, External: Acetaminophen and Codeine Generic: 0.1% (45 g) Outpatient Dosage Forms Gel, External: Solution, Oral [C-V]: Generic: 0.1% (45 g); 0.3% (45 g) Generic: Acetaminophen 120 mg and codeine phosphate 12 mg per 5 mL Lotion, External: (120 mL, 473 mL) [contains alcohol 7%] Generic: 0.1% (59 mL [DSC]) Tablet, Oral [C-III] : Adefovir Generic: Acetaminophen 300 mg and codeine phosphate 30 mg [BCF] Outpatient Dosage Forms AcetaZOLAMIDE Tablet, Oral, as dipivoxil: Outpatient Dosage Forms Generic: 10 mg Capsule Extended Release 12 Hour, Oral: Albendazole Generic: 500 mg Outpatient Dosage Forms Tablet, Oral: Tablet, Oral: Generic: 250 mg Generic: 200 mg Acetic Acid (Otic) Albuterol Outpatient Dosage Forms Outpatient Dosage Forms Solution, Otic: Aerosol Powder Breath Activated, Inhalation: Generic: 2% (15 mL) ProAir RespiClick: 90 mcg/actuation (1 ea) [contains milk protein] Acetic Acid, Propylene Glycol Diacetate, and Hydrocortisone Aerosol Solution, Inhalation: Outpatient Dosage Forms ProAir HFA: 108 (90 Base) mcg/actuation (8.5 g) [BCF] Syrup, Oral: Solution, Otic: Generic: 2 mg/5 mL (120 mL) Generic: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) Alclometasone Acetohydroxamic Acid Outpatient Dosage Forms Cream, External, as dipropionate: Outpatient Dosage Forms Generic: 0.05% (45 g) Tablet, Oral: Ointment, External, as dipropionate: Lithostat: 250 mg Generic: 0.05% (15 g, 60 g) Acetylcysteine Alcohol (Ethyl) Outpatient Dosage Forms Outpatient Dosage Forms Solution, Inhalation [preservative free]: Pad, External: Generic: 20% [200 mg/mL] (4 mL, 10 mL, 30 mL) Generic: 70% (100s) Acitretin Alendronate Outpatient Dosage Forms Outpatient Dosage Forms Capsule, Oral: Solution, Oral: Generic: 10 mg, 25 mg Generic: 70 mg/75 mL (75 mL) [BCF] Aclidinium Tablet, Oral: Generic: 5 mg [BCF], 10 mg [BCF], 35 mg [BCF], 70 mg [BCF] Outpatient Dosage Forms Aerosol Powder Breath Activated, Inhalation, as bromide: Alendronate and Cholecalciferol Tudorza Pressair: 400 mcg/actuation (1 ea) [contains lactose monohydrate] Outpatient Dosage Forms Tablet, Oral: Acyclovir and Hydrocortisone Fosamax Plus D: 70/5600: Alendronate 70 mg and cholecalciferol 5600 int. Outpatient Dosage Forms units Cream, External: Xerese: Acyclovir 5% and hydrocortisone 1% (5 g) [contains cetostearyl Alfuzosin alcohol, propylene glycol] Outpatient Formulary Brands Available Uroxatral 2 AMOXICILLIN AND CLAVULANATE Outpatient Dosage Forms Aminocaproic Acid Tablet Extended Release 24 Hour, Oral, as hydrochloride: Outpatient Dosage Forms Uroxatral: 10 mg [BCF] Solution, Oral: Generic: 10 mg [BCF] Generic: 25% (236.5 mL) Tablet, Oral: Alirocumab Generic: 500 mg Outpatient Formulary Brands Available Praluent Outpatient Dosage Forms Amiodarone Solution Auto-injector, Subcutaneous [preservative free]: Outpatient Formulary Brands Available Pacerone Praluent: 75 mg/mL (1 mL); 150 mg/mL (1 mL) [contains mouse (murine) and/ Outpatient Dosage Forms or hamster protein] Tablet, Oral, as hydrochloride: Pacerone: 200 mg [scored] [BCF] Aliskiren Generic: 200 mg [BCF] Outpatient Dosage Forms Tablet, Oral: Amitriptyline Generic: 150 mg, 300 mg Outpatient Dosage Forms Tablet, Oral, as hydrochloride: Allopurinol Generic: 10 mg [BCF], 25 mg [BCF], 50 mg [BCF], 75 mg [BCF], Outpatient Dosage Forms 100 mg [BCF] Tablet, Oral: Generic: 100 mg [BCF], 300 mg [BCF] AmLODIPine Outpatient Dosage Forms Alosetron Tablet, Oral: Outpatient Dosage Forms Generic: 2.5 mg [BCF], 5 mg [BCF], 10 mg [BCF] Tablet, Oral: Generic: 0.5 mg, 1 mg Amlodipine and Atorvastatin Outpatient Dosage Forms Alpelisib Tablet, Oral: Outpatient Dosage Forms Generic: Amlodipine 5 mg and atorvastatin 20 mg, Amlodipine 5 mg and Tablet Therapy Pack, Oral: atorvastatin 40 mg Piqray (300 MG Daily Dose): 2 x 150 MG (28 ea) Amlodipine and Benazepril ALPRAZolam Outpatient Formulary Brands Available Lotrel Outpatient Dosage Forms Outpatient Dosage Forms Concentrate, Oral: Capsule, Oral: ALPRAZolam Intensol: 1 mg/mL (30 mL) [unflavored flavor] Lotrel: Tablet, Oral: 2.5/10: Amlodipine 2.5 mg and benazepril hydrochloride 10 mg [BCF] Generic: 0.5 mg, 1 mg 5/10: Amlodipine 5 mg and benazepril hydrochloride 10 mg [BCF] Tablet Disintegrating, Oral: 5/20: Amlodipine 5 mg and benazepril hydrochloride 20 mg [BCF] Generic: 1 mg 5/40: Amlodipine 5 mg and benazepril hydrochloride 40 mg [BCF] Tablet Extended Release 24 Hour, Oral: 10/20: Amlodipine 10 mg and benazepril hydrochloride 20 mg [BCF] Generic: 0.5 mg, 1 mg 10/40: Amlodipine 10 mg and benazepril hydrochloride 40 mg [BCF] Generic: Alprostadil 2.5/10: Amlodipine 2.5 mg and benazepril hydrochloride 10 mg [BCF] Outpatient Dosage Forms 5/10: Amlodipine 5 mg and benazepril hydrochloride 10 mg [BCF] Kit, Intracavernosal: 5/20: Amlodipine 5 mg and benazepril hydrochloride 20 mg [BCF] Caverject Impulse: 10 mcg (2/box) [contains benzyl alcohol, lactose] 5/40: Amlodipine 5 mg and benazepril hydrochloride 40 mg [BCF] Edex: 10 mcg (1 ea), 20 mcg (1 ea), 40 mcg (1 ea) [pyrogen free; contains 10/20: Amlodipine 10 mg and benazepril hydrochloride 20 mg [BCF] lactose] 10/40: Amlodipine 10 mg and benazepril hydrochloride 40 mg [BCF] Pellet, Urethral: Amlodipine and Olmesartan Muse: 500 mcg (6 ea); 1000 mcg (6 ea) Outpatient Dosage Forms Solution, Injection: Tablet, Oral: Generic: 500 mcg/mL (1 mL) Generic: Amlodipine 10 mg and olmesartan medoxomil 20 mg, Amlodipine Solution Reconstituted, Intracavernosal: 10 mg and olmesartan medoxomil 40 mg, Amlodipine 5 mg and olmesartan Caverject: 40 mcg (1 ea) [contains benzyl alcohol, lactose] medoxomil 40 mg Aluminum Chloride Hexahydrate Amlodipine and Valsartan Outpatient Formulary Brands Available Drysol Outpatient Dosage Forms Outpatient Dosage Forms Tablet, Oral: Solution, External: Generic: Amlodipine 10 mg and valsartan 320 mg, Amlodipine 5 mg and Drysol: 20% (37.5 mL, 60 mL) valsartan 160 mg, Amlodipine 5 mg and valsartan 320 mg Amoxicillin Amantadine Outpatient Dosage Forms Capsule, Oral: Outpatient Dosage Forms Generic: 250 mg [BCF], 500 mg [BCF] Suspension Reconstituted, Oral: Capsule, Oral, as hydrochloride: Generic: 125 mg/5 mL; 250 mg/5 mL [BCF]; 400 mg/5 mL [BCF] Generic: 100 mg [BCF] Syrup, Tablet, Chewable, Oral: Oral, as hydrochloride: Generic: 250 mg Tablet, Oral: Generic: 50 mg/5 mL [BCF] Generic: 875 mg AMILoride Amoxicillin and Clavulanate Outpatient Formulary Brands Available Augmentin; Augmentin ES-600 Outpatient Dosage Forms Outpatient Dosage Forms Suspension Reconstituted, Oral: Tablet, Oral, as hydrochloride: Augmentin: Generic: 5 mg 125: Amoxicillin 125 mg and clavulanate potassium 31.25 mg per 5 mL (75 mL, 100 mL, 150 mL) [contains potassium 0.16 mEq/5 mL; banana Amiloride and Hydrochlorothiazide flavor] [BCF] Augmentin ES-600: Amoxicillin 600 mg and clavulanate potassium 42.9 mg Outpatient Dosage Forms per 5 mL (125 mL, 200 mL) [contains phenylalanine 7 mg/5 mL and potassium 0.23 mEq/5 mL; strawberry cream flavor] Tablet: 5/50: Amiloride hydrochloride 5 mg and hydrochlorothiazide 50 mg Generic: 200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg per 5 mL (50 mL, 75 mL, 100 mL) [BCF] 3 AMOXICILLIN AND CLAVULANATE 400: Amoxicillin 400 mg and clavulanate potassium 57 mg per 5 mL (50 mL, Outpatient Dosage Forms 75 mL, 100 mL) [BCF] Tablet, Oral: 600: Amoxicillin 600 mg and clavulanate potassium 42.9 mg per 5 mL (75 Evotaz: Atazanavir 300 mg and cobicistat 150 mg mL, 125 mL, 200 mL) [BCF] Tablet, Oral: Atenolol Generic: Outpatient Dosage Forms Amoxicillin 250 mg and clavulanate potassium 125 mg [BCF] Tablet, Oral: Amoxicillin 500 mg and clavulanate potassium 125 mg [BCF] Generic: 25 mg [BCF], 50 mg [BCF],
Load more

Recommended publications
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • Alphabetical Listing by Therapeutic Category GOODFELLOW AFB ROSS CLINIC FORMULARY
    GOODFELLOW AFB ROSS CLINIC FORMULARY Alphabetical Listing by Therapeutic Category This document is current as of October 8, 2020. The availability of formulary items is subject to change. ACARBOSE Acarbose ALPRAZolam Outpatient Dosage Forms Outpatient Formulary Brands Available Xanax Tablet, Oral: Outpatient Dosage Forms Generic: 25 mg, 50 mg, 100 mg Tablet, Oral: Xanax: 0.5 mg, 1 mg [scored] Acetaminophen Generic: 0.5 mg, 1 mg Outpatient Formulary Brands Available Mapap Children's [OTC]; Mapap [OTC] Aluminum Chloride Hexahydrate Outpatient Dosage Forms Outpatient Formulary Brands Available Drysol Suspension, Oral: Outpatient Dosage Forms Mapap Children's: 160 mg/5 mL (118 mL) [ethanol free; contains propylene Solution, External: glycol, sodium benzoate; cherry flavor] Drysol: 20% (60 mL) Tablet, Oral: Mapap: 325 mg Aluminum Hydroxide, Magnesium Hydroxide, and Simethicone Generic: 325 mg Outpatient Dosage Forms Liquid, Oral: Acetaminophen and Codeine Generic: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and Outpatient Dosage Forms simethicone 20 mg per 5 mL (360 mL) Solution, Oral [C-V]: Generic: Acetaminophen 120 mg and codeine phosphate 12 mg per 5 mL Amantadine (118 mL) [BCF] Outpatient Dosage Forms Tablet, Oral [C-III]: Capsule, Oral, as hydrochloride: Generic: Acetaminophen 300 mg and codeine phosphate 30 mg [BCF] Generic: 100 mg [BCF] AcetaZOLAMIDE Amiodarone Outpatient Dosage Forms Outpatient Dosage Forms Tablet, Oral: Tablet, Oral, as hydrochloride: Generic: 250 mg Generic: 200 mg [BCF] Acetic Acid, Propylene Glycol Diacetate,
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,641,839 B1 Geoghegan Et Al
    USOO6641839B1 (12) United States Patent (10) Patent No.: US 6,641,839 B1 Geoghegan et al. (45) Date of Patent: Nov. 4, 2003 (54) PHARMACEUTICAL FORMULATIONS FOR JP 59 84.820 5/1984 PREVENTING DRUG TOLERANCE JP 62126127 * 6/1987 (75) Inventors: Edward James Geoghegan, Athlone OTHER PUBLICATIONS (IE); Seamus Mulligan, Athlone (IE); “Isosorbide-5-Nitrate Sustained-release pellets-an Mary Margaret Foynes, Athlone (IE) example of computer Supported drug development', Zerbe et al., Pharmacuetical Resarch 1985, No. 1, Jan., pp. 30–36. (73) Assignee: Athpharma Limited, Roscommon (IE) “Glyceryl trinitrate (nitroglycerine) and the Organic nitrates choosing the method of administration”, J. Abrahms, Drugs (*) Notice: Subject to any disclaimer, the term of this 34; 391-403 (1987). patent is extended or adjusted under 35 “Dose Dependence of Tolerance during treatment with U.S.C. 154(b) by 407 days. mono-nitrates', M. Tauchert et al., Z. Cardiol. 72, Suppl. 3, 218–228 (1983). (21) Appl. No.: 08/797,318 “Tolerance Development during isosorbide dinitrate treat ment: Can it be circumvented?”, W. Rudolf et al., Z. Cardiol. (22) Filed: Feb. 7, 1997 72, Supple. 3, 195-198 (1983). Related U.S. Application Data “Anti-ischemic effects of 80mg tablet of isosorbide dinitrate in Sustained-release form before and after two weeks treat (63) Continuation of application No. 08/419,520, filed on Apr. ment with 80mg once daily or twice daily', S.Silver et al., 10, 1995, which is a continuation of application No. 08/320, Z.Cardiol. 72, Suppl. 3, 211-217 (1983). 599, filed on Oct. 11, 1994, which is a continuation of application No.
    [Show full text]
  • Cardiovascular Drugs and Therapies NITRATES COMPARISON CHART
    Cardiovascular Drugs and Therapies NITRATES COMPARISON CHART Isosorbide Generic Nitroglycerin Nitroglycerin Nitroglycerin Nitroglycerin Dinitrate Isosorbide Isosorbide Name Intravenous Patch Ointment Sublingual Sublingual Dinitrate 5-Mononitrate Trade Name TRIDIL, NITRODUR, NITROL NITROLINGUAL generics generics (for IMDUR, generics TRANSDERM- Pumpspray, immediate generics NITRO, RHO-NITRO release) MINITRAN, Pumpspray, SR: no longer TRINIPATCH NITROLINGUAL available Metered dose spray NITROSTAT sublingual tablet Dosage 100 mg/250 mL 0.2 mg/h 30 g/30 inches SL spray: SL tablet: 5mg Immediate SR tablet: Forms premixed bottle 0.4 mg/h ointment 0.4 mg/ dose release 60 mg SR - UHN 0.6 mg/h SL tablet: tablet: Note: 0.84 mL 0.8 mg/h 0.3 mg, 0.6 mg 10 mg *Non- alcohol per 100 mL 30 mg formulary at solution UHN 100 mcg/mL 200 mcg/mL 400 mcg/mL 10 mg/10 mL vial - UHN 50 mg/10 mL vial - UHN CARDIOVASCULAR PHARMACOTHERAPY HANDBOOK All contents copyright © University Health Network. All rights reserved Cardiovascular Drugs and Therapies NITRATES COMPARISON CHART Isosorbide Generic Nitroglycerin Nitroglycerin Nitroglycerin Nitroglycerin Dinitrate Isosorbide Isosorbide Name Intravenous Patch Ointment Sublingual Sublingual Dinitrate 5-Mononitrate Dosing Starting and 0.2 to 0.8 ½ inch to 1 inch SL spray: SL tablet: Immediate 60-240 mg SR Usual dose target doses mg/h once tid-qid; remove 0.4 mg prn; 5-10 mg q2-4h release: once daily range are determined daily. for 8-10 hours dose may be for prophylaxis 10-45 mg tid by clinical per 24-hour repeated after of acute angina on qid situation and 12-14 hour period; 5 minutes for schedule the number and patch-free response to interval e.g., ON 0600, total of 3 doses (e.g.
    [Show full text]
  • 2013 ESC Guidelines on the Management of Stable Coronary
    European Heart Journal Advance Access published August 30, 2013 European Heart Journal ESC GUIDELINES doi:10.1093/eurheartj/eht296 2013 ESC guidelines on the management of stable coronary artery disease The Task Force on the management of stable coronary artery disease of the European Society of Cardiology Task Force Members: Gilles Montalescot* (Chairperson) (France), Udo Sechtem* (Chairperson) (Germany), Stephan Achenbach (Germany), Felicita Andreotti (Italy), Chris Arden (UK), Andrzej Budaj (Poland), Raffaele Bugiardini (Italy), Filippo Crea Downloaded from (Italy), Thomas Cuisset (France), Carlo Di Mario (UK), J. Rafael Ferreira (Portugal), Bernard J. Gersh (USA), Anselm K. Gitt (Germany), Jean-Sebastien Hulot (France), Nikolaus Marx (Germany), Lionel H. Opie (South Africa), Matthias Pfisterer (Switzerland), Eva Prescott (Denmark), Frank Ruschitzka (Switzerland), Manel Sabate´ http://eurheartj.oxfordjournals.org/ (Spain), Roxy Senior (UK), David Paul Taggart (UK), Ernst E. van der Wall (Netherlands), Christiaan J.M. Vrints (Belgium). ESC Committee for Practice Guidelines (CPG): Jose Luis Zamorano (Chairperson) (Spain), Stephan Achenbach (Germany), Helmut Baumgartner (Germany), Jeroen J. Bax (Netherlands), He´ctor Bueno (Spain), Veronica Dean (France), Christi Deaton (UK), Cetin Erol (Turkey), Robert Fagard (Belgium), Roberto Ferrari (Italy), David Hasdai (Israel), Arno W. Hoes (Netherlands), Paulus Kirchhof (Germany/UK), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Patrizio Lancellotti (Belgium), Ales Linhart (Czech Republic), Petros Nihoyannopoulos (UK), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Per Anton Sirnes (Norway), Juan Luis Tamargo (Spain), Michal Tendera (Poland), by guest on September 16, 2015 Adam Torbicki (Poland), William Wijns (Belgium), Stephan Windecker (Switzerland). Document Reviewers: Juhani Knuuti (CPG Review Coordinator) (Finland), Marco Valgimigli (Review Coordinator) (Italy), He´ctor Bueno (Spain), Marc J.
    [Show full text]
  • Exogenous Nitric Oxide Inhibits Rho-Associated Kinase Activity in Patients with Angina Pectoris: a Randomized Controlled Trial
    Hypertension Research (2015) 38, 485–490 & 2015 The Japanese Society of Hypertension All rights reserved 0916-9636/15 www.nature.com/hr ORIGINAL ARTICLE Exogenous nitric oxide inhibits Rho-associated kinase activity in patients with angina pectoris: a randomized controlled trial Tatsuya Maruhashi1,5, Kensuke Noma2,5, Noritaka Fujimura1, Masato Kajikawa1, Takeshi Matsumoto1, Takayuki Hidaka1, Ayumu Nakashima3, Yasuki Kihara1, James K Liao4 and Yukihito Higashi2 The RhoA/Rho-associated kinase (ROCK) pathway has a key physiological role in the pathogenesis of atherosclerosis. Increased ROCK activity is associated with cardiovascular diseases. Endogenous nitric oxide (NO) has an anti-atherosclerotic effect, whereas the exogenous NO-mediated cardiovascular effect still remains controversial. The purpose of this study was to evaluate the effect of exogenous NO on ROCK activity in patients with angina pectoris. This is a prospective, open-label, randomized, controlled study. A total of 30 patients with angina pectoris were randomly assigned to receive 40 mg day − 1 of isosorbide mononitrate (n = 15, 12 men and 3 women, mean age of 63 ± 12 years, isosorbide mononitrate group) or conventional treatment (n = 15, 13 men and 2 women, mean age of 64 ± 13 years, control group) for 12 weeks. ROCK activity in peripheral leukocytes was measured by western blot analysis. ROCK activities at 4 and 12 weeks after treatment were decreased in the isosorbide mononitrate group (0.82 ± 0.33 at 0 week, 0.62 ± 0.20 at 4 weeks, 0.61 ± 0.19 at 12 weeks, n = 15 in each group, Po0.05, respectively) but not altered in the control group. ROCK1 and ROCK2 expression levels were similar in all treatment periods in the two groups.
    [Show full text]
  • Use of Sildenafil in Patients with Cardiovascular Disease
    Arq Bras Cardiol GuimarãesReview et al volume 73, (nº6), 1999 Sildenafil in patients with cardiovascular disease Use of Sildenafil in Patients with Cardiovascular Disease Armênio Costa Guimarães, Marcus Vinícius Bolívar Malachias, Otávio Rizzi Coelho, Emílio Cesar Zilli, Rafael Leite Luna Introduction of phosphodiesterase inhibitors. The erectile action of sildenafil combines increase in arterial flow with reduction Erectile dysfunction, formerly called impotence, is the in the venous flow of cavernous body of penis. Sildenafil inability of the male to achieve or maintain penile erection and leads to relaxation of smooth muscle of penile arteries and thus engage in coitus1. It is common among patients with trabeculae surrounding the sinusoidal spaces, resulting in cardiovascular diseases or their risk factors. This dysfunc- a greater engorgement of cavernous body. The trabeculae tion occurs mainly among individuals with coronary artery of engorged sinusoidal spaces compress the penile disease, after episodes of acute ischemic syndrome, hyper- venules against the tunica albuginea, reducing venous tensive patients underpharmacologic treatment, and among flow, contributing to maintenance of engorgement of patients with heart failure. In approximately 85% of these ca- cavernous body8. Relaxation of this smooth muscle ses, the fear of a cardiac event during coitus constitutes an results from a decrease in intracellular calcium mediated important factor for erectile dysfunction 2-4. by accumulation of the second messenger, the cyclic Discovery of sildenafil citrate has represented a great de- guanosine monophosphate (cGMP), whose production velopment in the treatment of erectile dysfunction; it may results from activation of guanyl cyclase by nitric oxide benefit, among many others, those patients with cardiovascu- produced by the stimulus of endothelial cells generated lar diseases or with their risk factors 5.
    [Show full text]
  • Management of Stable Angina in Adults
    Management of Stable Angina in Adults For new onset chest pain where angina is suspected patients should be referred to Rapid Access Chest Pain Service. ANTIANGINAL DRUG TREATMENT *see West Essex formulary for further choices Monotherapy: Beta blocker [Bisoprolol*] OR Calcium channel blocker (CCB) [Amlodipine*] N.B. In left-ventricular dysfunction (LVD), beta blocker therapy should be started at a low dose and titrated very slowly over a period of weeks or months. If beta-blockers or CCBs are not tolerated or both are contra- If a beta-blocker or Calcium Channel Blocker is indicated consider monotherapy with: contraindicated or not tolerated or symptoms are not a long-acting nitrate e.g. Isosorbide mononitrate MR controlled with a beta-blocker or CCB: Nicorandil Switch to the alternative drug Ivabradine (Restricted use – consultant initiation) or Ranolazine (Restricted use – consultant initiation) Do not combine ivabradine with a rate-limiting CCB, because it can Dual therapy: result in excessive bradycardia. Beta blocker AND Calcium Channel Blocker If symptoms are not controlled with a beta-blocker or If symptoms are not controlled with a beta-blocker or CCB alone DRUG THERAPY DRUG CCB, and neither are contraindicated: give a beta- and the other drug is contraindicated or not tolerated ADD: blocker AND CCB in combination. a long-acting nitrate or Do not combine a beta-blocker with a rate limiting Nicorandil CCB, as severe bradycardia and heart failure can Ivabradine (Restricted use – consultant initiation) or occur.3 Ranolazine (Restricted use – consultant initiation) NOTE Assess response to treatment 2-4 weeks after initiating or changing drug therapy; the drug should be titrated (according to symptom control) to the maximum tolerated dose.
    [Show full text]
  • (12) Patent Application Publication (48) Pub
    US 20090226407A9 (19) United States (10) Pub. No.: US 2009/0226407 A9 (12) Patent Application Publication (48) Pub. Date: Sep. 10, 2009 L0ScalZ0 et al. CORRECTED PUBLICATION (54) METHODS OF TREATING VASCULAR (60) Provisional application No. 60/179,020, filed on Jan. DISEASES CHARACTERIZED BY NITRC 31, 2000. Provisional application No. 60/162,230, OXIDE INSUFFICIENCY filed on Oct. 29, 1999. Provisional application No. 60/179,020, filed on Jan. 31, 2000. Provisional appli (76) Inventors: Joseph Loscalzo, Dover, MA (US); cation No. 60/162,230, filed on Oct. 29, 1999. Joseph A. Vita, Hingham, MA (US); Michael D. Loberg, Boston, MA (US); Publication Classification Manuel Worcel, Boston, MA (US) (51) Int. Cl. Correspondence Address: A6II 38/43 (2006.01) WILMERHALEANTROMED AOIN 43/04 (2006.01) 1875 PENNSYLVANIAAVE, NW (52) U.S. Cl. .............................................. 424/94.1: 514/23 WASHINGTON, DC 20006 (US) (21) Appl. No.: 10/692,724 (57) ABSTRACT (22) Filed: Oct. 27, 2003 The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency Prior Publication Data by administering atherapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nit (15) Correction of US 2004/0105850 A1 Jun. 3, 2004 rosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated See (60) Related U.S. Application Data. endothelin antagonist, nitrosated angiotensin II receptor (65) US 2004/0105850 A1 Jun. 3, 2004 antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at Related U.S. Application Data least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers (60) Continuation-in-part of application No.
    [Show full text]
  • Module5-Nitrates-Nitroglycerin.Pdf
    Drug Information Table Nitrates – nitroglycerin, isosorbide (Isordil) Therapeutic Use Administration • Treatment and prophylaxis of • Nitroglycerin available as angina pectoris sublingual tablets, sustained- ◦ Rapid-acting forms (only release capsules or tablets, transmucosal tablets, a translingual spray or translingual spray and transmucosal tablets, sublingual tablets treat an transdermal ointment or patch, angina attack) and IV form ◦ Longer acting forms such as • Two types of isosorbide are regular tablets, immediate available release or sustained release ◦ isosorbide dinitrate (Isordil) tablets/capsules are used to available in regular, chewable, prevent attacks from occurring sublingual or sustained • IV nitroglycerin is used for release tablets. severe unstable angina attacks ◦ isosorbide mononitrate ((Ismo, and to control blood pressure Imdur) available in sustained perioperatively and to treat release and immediate heart failure after acute MI release tablets or capsules • Place sublingual tablets under tongue to dissolve when chest pain starts; if not relieved in 5 minutes, call 911, take a second tablet; take a third tablet 5 minutes later if no relief • Sublingual sprays: Dose equals 1 or 2 sprays; as for sublingual tablets, no more than 3 doses in a 15 minute period • Patient should not swallow transdermal or transmucosal tablets; may need to moisten mouth to help tablet dissolve • Store tablets in a dark tightly closed container for no more than 24 months after opening. • Transdermal patches are for prevention only; apply to a hairless area and rotate sites. • Remove patches for 10-12 hours daily to prevent tolerance; apply patch in morning, remove at night. • Topical ointment: dosage measured as amount squeezed from tube (e.g.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,635,273 B1 Loscalz0 Et Al
    USOO6635273B1 (12) United States Patent (10) Patent No.: US 6,635,273 B1 LOScalZ0 et al. (45) Date of Patent: Oct. 21, 2003 (54) METHODS OF TREATING VASCULAR Dries et al, The New England Journal of Medicine, DISEASES CHARACTERIZED BY NITRIC 340(8):609-616 (Feb. 25, 1999). OXDE INSUFFICIENCY Freedman et al, Drugs, 54(Supp. 3):41-50 (1997). Sherman et al., Cardiologia, 42(2):177-187 (1997). (75) Inventors: Joseph Loscalzo, Dover, MA (US); Biegelson et al., Coronary Artery Disease, 10:241-256 Joseph A. Vita, Hingham, MA (US); (1999). Michael D. Loberg, Boston, MA (US); Rudd et al, Am. J. Physiol., 277(46):H732–H739 (1999). Manuel Worcel, Boston, MA (US) Hammerman et al, Am. J. Physiol., 277(46):H1579-H1592 (1999). (73) Assignees: Trustees of Boston University, Boston, LoScalzo et al., Transactions of the American and Climato MA (US); NitroMed, Inc., Bedford, logical ASS., 111:158-163 (2000). MA (US) Cohn et al, The New England Journal of Medicine, 325(5):303-310 (1991). (*) Notice: Subject to any disclaimer, the term of this Cohn et al, The New England Journal of Medicine , patent is extended or adjusted under 35 314(24): 1547–1552 (1986). U.S.C. 154(b) by 0 days. Carson et al., Circulation, Supplement I, 92(8):I31-I32, Abstract No. 0145 (1995). (21) Appl. No.: 09/697,317 (List continued on next page.) (22) Filed: Oct. 27, 2000 Primary Examiner-Jon P. Weber Related U.S. Application Data ASSistant Examiner-Kalash C. Srivastava (60) Provisional application No. 60/179,020, filed on Jan.
    [Show full text]